Scam, kidnap by South African police

Scam, kidnap by South African police

Medical Writing Institute click here

MJoTAtalks click here

Emerald Pademelon Press LLC click here

Peace Scientists click here

Dr Susanna loves the countries and the peoples of Africa

Scam, kidnap by South African police

Scam, kidnap by South African police

Bookmark and Share
Constantly updated health news, click here.
Links to HIV/AIDS resources and articles published by MJoTA since 2007 click here.
Diabetes resources, click here
Asthma resources, click here
HIV/AIDS. SJ Dodgson MJoTA 2013 v7n2 p1203

When I was laying out pages on Zambia and the Peace Corps, I came across a disturbing story of a returned Peace Corps volunteer who was in Zambia for less than 3 months when she was diagnosed with HIV infection, and sent back to the United States.

She had met a man and said she only had sex with him once. She did not believe that she had sex with him more than that, although she admitted before she finally decided she was comfortable enough with him to have "sex" she had orally satisfied him on two occasions. Taking his body fluids into her mouth. That is sex, and that is dangerous.

I have been looking through the scientific literature which is surprisingly silent on the risk of HIV infection through orally satisfying a man. Is the risk low? High? I don't care. The risk is there.

Don't orally satisfy a man without using a condom. Or anally satisfy. Or vaginally satisfy. Or exchange body fluids. If you are tied to him by a short string for months, years, or live on a small island with no access to the outside world (or condoms), or both are eager for children, you can not use a condom.

Of course, any insistence on stepping away or rigorous condom use on a woman's part can only be accepted if the woman has the power to say no. Peace Corps workers do have that power. So does every woman in the United States.

HIV Therapies. SJ Dodgson. The Journal of the European Medical Writers Association. 2003. v12.

I first heard of the HIV epidemic in the summer of 1981 when I was listening to the radio while bathing my first-born child in the kitchen sink in my apartment in Philadelphia. The Centers for Disease Control reported a strange epidemic in homosexual men, later, the risk group included Haitians, still later, intravenous drug users and now, whole African countries like Botswana. As the years passed, the main risk groups changed and life-prolonging medications have become available in rich, industrialized countries. One theme remains constant: AIDS is a deadly disease and infected persons can become resistant to all the therapies.

Two gay men living next-door to me in Sydney when I was finishing my PhD thesis are gone. I visited them when I went back to Sydney with my children in 1982 and 1983, we discussed day-to-day events and our futures as if I had never left.

For me, HIV/AIDS is about two young men, friends since kindergarten, who never reached 50, or even 40. And especially about Ian, who was gorgeous looking and loved by many men. Ian made dresses and cooked for us and learned Italian so he could teach in Italy but instead with good grace taught English in Turkey where he was sent by the New South Wales Department of Education. Graeme was monogamous and left teaching to work in the phone company. He didn’t reach 40 either.

During the early years of the epidemic I was involved in investigating carbon dioxide handling in the body. I identified mechanisms of carbon dioxide fixing and releasing in the liver, kidney, and brain and confirmed that these mechanisms work in neutrophils, which are involved in the immune system. Do they also work in CD4+ cells? Probably. I can state confidently that therapeutically disrupting the carbon dioxide handling mechanisms of the immune cells that the HIV virus hijacks has never been under serious consideration. The HIV virus is tough and when its DNA takes over a CD4+ cell, what it does is reproduce virus and destroy the ability of the body to defend itself against bacteria, fungi, other viruses and cancer. The virus rapidly evolves and rapidly can become resistant to one treatment after another.

I started full-time writing about HIV a week after the devastating cascade of events that started when 2 passenger airlines smashed themselves between upper floors of 20% of New York City office-space.

The immediate consequences of these smashes and the 2 following in Pennsylvania and Washington DC was a scaling-back of marketing writing in the center of the pharmaceutical industry, which is surrounded geographically by New York City, Pennsylvania, Washington DC and the Atlantic Ocean.

The immediate consequence to me was that within a week, the disease monographs I was writing for an advertising agency were no longer needed and a medical communications company needed a medical writer who would travel by air for their client in California.

Ten days later, I flew to southern California for a consultant meeting. The next morning the account executive drove us both north along the coast of California, past Los Angeles, to Santa Barbara to a resort, which were arguably my most luxurious accommodations. I enjoyed walking past the oleander and rhododendrons before diving into a swimming pool, then hanging out in a hot tub before bathing in my room while watching candles in the fireplace and the palm trees over the balcony at the same time. After listening to talks about the treatment of HIV from a psychiatrist, an HIV resistance specialist and a lipodystrophy specialist. The meals were terrific too.

The work with the medical communications company only improved. On the heels of the conferences in California was the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. A meeting with the client in Santa Barbara revealed their desire to have a presence at the meeting in Athens as well as their reluctance to send any of their own employees.

I think the whole September 11 disaster was easier on those of us who were in the middle of it; we saw what happened and we saw it being cleaned up.

Three thousand miles away in California all they knew was that all of the 4 passenger airliners that crashed were headed for California. I was not quiet about my desire to represent my favorite pharmaceutical company and report on the Athens meeting and so, two weeks later, I stepped off a plane in Athens.

The need for an annual lipodystrophy conference since 1999 highlights the consequences of taking drugs to control HIV infection. The first two classes of HIV drugs are retroviral inhibitors: the nucleotide retroviral inhibitors (NRTIs) and the non-nucleotide retroviral inhibitors (NNRTIs). The first drug with any controlling effect on HIV is known as AZT or ZDV or zidovudine. AZT was approved by the US Food and Drug Administration in 1987, since then other NRTIs have been approved and this class remains the largest. The approval of a third group of HIV drugs in 1995, the protease inhibitors, was earth-shaking for those affected with HIV and those treating affected persons. For the first time, health care providers were not routinely burying their infected patients.

Since 1995 the treatment of choice is a drug cocktail, called by the US Department of Health and Human Services Highly Active Anti-Retroviral Therapy, or HAART. This cocktail includes 3 or 4 drug cocktails from one or more classes. Since 1995, persons infected with HIV on HAART are living longer, but those infected are still at risk for premature death.

In the 1980s, HIV infection meant that death from AIDS probably would follow within 5 to 10 years. In the past few years, persons infected with HIV and treated with HAART have had increased likelihood of cardiovascular events. The question about whether the cardiovascular events result from the HIV infection or from HAART drugs remains unanswered.

In May I sent daily reports from Digestive Disease Week in San Francisco, summarizing talks on treatments for hepatitis C and HIV co-infection. The rate of co-infection is increasing, and liver failure is now the number 1 cause of death of persons infected with HIV.

The 14th International AIDS Conference in Barcelona in July was huge and all the pharmaceutical companies were well-represented. I summarized 12 symposia in which consultants presented the industry’s newest therapies. We heard about progress towards producing a viable anti-HIV vaccine. We are not yet there, but clinical trials are proceeding and within 12 months we will know if one or more vaccines are fulfilling their early promise. Other classes of anti-HIV drugs were described, the fusion inhibitors which prevent the HIV virus from inserting its DNA into CD4+ cells and the integrase inhibitors, which prevent reproduction of the virus inside the CD4+ cell.

The most exciting part of the conference to me was sitting next to infected persons who would have been dead 10 years ago. The bottom line is that Ian and Graeme would have had a good possibility of living to 40, or 50 if they had been infected 10 years later.

I was sitting in the hot-tub in Santa Barbara in October 2001, chatting with 2 HIV physicians about the oil I had tracked from the beach into the bath-tub. I assumed that the oil resulted from some tanker spill somewhere; one of the physicians told me that the oil pre-dated settlement by Europeans, and that native Americans used it to water-proof boats. These boats were leaky and the trick was to land somewhere before the boats were swamped.

Which describes HIV therapies. HIV is a tricky disease to treat because infected persons either do not have access to treatment (a major problem in developing countries) or they can become resistant to one treatment after another. All we can hope for anyone infected is that they can stay afloat until they reach land.

This essay was first published by the European Medical Writers Association in 2003 in The Write Stuff.

Mr Amadou Diagne. SJ Dodgson. MJoTA 2012 v6n1 p0412

The man from Gilead Pharmaceutical Company was at the African Caribbean Business Council Forum today, Apr 12, 2012, giving his talk about the threat and treatment of HIV/AIDS.

He is Mr Amadou Diagne, Associate Director, Medical Sciences, at Gilead Sciences Inc.

I have now heard him 4 times, in New York, Pennsylvania and New Jersey, and seen him at other African community events. He is passionate about preventing HIV/AIDS in African Diaspora communities, and he told me today he has had feedback from several who had not known they were infected, but sought testing and treatment after listening to him.

Ah, as I told him, and also Philadelphia's wonderful Ghanaian foot doctor and educator (he started schools in Accra and Philadelphia, and inducts Ghanaian Queens and Kings), Dr Samuel Quartey: if only drug companies selling high blood pressure medicines and diabetes medicines would sponsor health professionals to aggressively seek out African communities to warn against cardiovascular disease.

Cardiovascular disease is killing more adults in African communities than HIV/AIDS.

HIV/AIDS prevention and treatment of HIV infection is working, because it could easily have become the number one killer. Before antiretroviral drugs and the Herculean efforts of President Bill Clinton and other former country politicians, HIV infection was set to be the main killer, click here.

HIV/AIDS resources click here.
December 1st: World AIDS Day. Remembering the millions killed by this disease, and the enormous advances in medical science that have resulted in HIV/AIDS being treated as a chronic disease. If you have the drugs, and you take them every time you are meant to, you can live a normal life span. Make your life count, so many have died, and are dying, without access to HIV/AIDS medicines and healthcare.
Below are articles from a continuous feed from the CDC, which is the United States Department of Health Centers for Disease Control and Prevention. They are the largest health data gathering organization on the planet.

Latest Top (20) News

HIV Among Women
This web content provides statistical data and information about HIV among women in the United States, including a fact sheet that visually displays this information.

Fri, 09 Mar 2018 12:00:00 EST

Dear Colleague: National Women and Girls HIV/AIDS Awareness Day
March 10 is National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), a time when organizations and communities across the United States come together to offer support, encourage discussion, and teach women and girls about the prevention of HIV, the importance of getting tested, and how to live with and manage HIV infection.

Fri, 09 Mar 2018 10:00:00 EST

HIV Prevention With Health Departments
CDC's domestic HIV funding for 2018 will support HIV surveillance and prevention efforts led by health departments in states, territories, and selected cities.

Thu, 08 Mar 2018 13:30:01 EST

HIV Prevention in the South
CDC's domestic HIV funding for 2018 in the Southern United States will strengthen HIV prevention efforts in the region that bears the greatest burden of HIV.

Thu, 08 Mar 2018 13:30:00 EST

Internalized HIV-Related Stigma Fact Sheet
Almost 8 in 10 HIV patients in the United States report feeling internalized HIV-related stigma. Learn more about how people living with HIV can reduce internalized stigma.

Fri, 23 Feb 2018 09:45:00 EST

HIV Diagnoses Among Persons Aged 13–29 Years — United States, 2010–2014
HIV diagnoses analyzed by age groups revealed striking differences in rates of diagnosis of HIV infection between ages 13–21 years. During 2010–2014, HIV infection diagnosis rates per 100,000 population varied substantially with increasing age among persons aged 13–15 years (0.7), 16–17 years (4.5), 18–19 years (16.5), and 20–21 years (28.6). HIV diagnosis rates were higher, but less variable, among persons aged 22–23 years (34.0), 24–25 years (33.8), 26–27 years (31.3), and 28–29 years (28.7).

Thu, 22 Feb 2018 16:15:00 EST

Injection Drug Use and HIV Risk
This page describes the risk of getting HIV from injection drug use (sharing needles, syringes, and other injection equipment).

Wed, 21 Feb 2018 07:00:00 EST

HIV Among People Who Inject Drugs
This fact sheet presents data on HIV in the United States among people who inject drugs, describes the risk of getting HIV from injection drug use, and discusses CDC’s work to prevent HIV.

Tue, 20 Feb 2018 15:30:00 EST

2016 Monitoring and Evaluation Report Comprehensive HIV Prevention Programs for Health Departments PS12-1201
An overview of progress on selected PS12-1201required and recommended program components in 61 CDC-funded health departments in the United States, Puerto Rico, and the U.S. Virgin Islands, 2016.

Thu, 15 Feb 2018 11:45:00 EST

HIV and African Americans
This fact sheet provides information about HIV among African Americans.

Wed, 07 Feb 2018 09:16:00 EST

HIV and African American Gay and Bisexual Men
This fact sheet provides information about HIV among African American gay and bisexual men.

Wed, 07 Feb 2018 09:15:00 EST

Dear Colleague: National Black HIV/AIDS Awareness Day
February 7 is National Black HIV/AIDS Awareness Day. Read more about HIV among African Americans and what CDC and its partners are doing.

Tue, 06 Feb 2018 13:15:00 EST

Racial and Ethnic Disparities in Sustained Viral Suppression and Transmission Risk Potential Among Persons Receiving HIV Care — United States, 2014
In 2014, fewer blacks living with diagnosed HIV infection had sustained viral suppression (all viral load test results in 2014 less than 200 HIV RNA copies per mL) compared with Hispanics and whites. Among those who were in care and did not achieve sustained viral suppression, blacks had viral loads greater than 1,500 copies per mL for approximately half of the 12-month period in 2014; this circumstance can adversely affect their health outcomes and pose a risk for further transmission. Blacks aged 13–24 years had the lowest prevalence of sustained viral suppression.

Thu, 01 Feb 2018 13:50:00 EST

Notes from the Field: Public Health Response to a Human Immunodeficiency Virus Outbreak Associated with Unsafe Injection Practices — Roka Commune, Cambodia, 2016
Cambodians receive 0.8–5.9 therapeutic injections per person per year, one of the highest reported rates worldwide. Appropriate medical injections and infusions can be health sustaining or lifesaving; however, improper administration can have detrimental health consequences, including infectious disease transmission. In 2000, it was estimated that worldwide, unsafe injection and waste disposal practices account for 260,000 new human immunodeficiency virus (HIV) infections annually.

Thu, 01 Feb 2018 13:45:00 EST

Pediatric HIV Surveillance (through 2016)
This slide set describes HIV among children younger than 13 years in the United States and 6 dependent areas.

Mon, 29 Jan 2018 13:45:00 EST

Notice of Funding Opportunity (NOFO) PS18-1802: Integrated HIV Surveillance and Prevention Programs for Health Departments Component A Funding Table
Annual funding amounts for PS18-1802 award recipients.

Fri, 19 Jan 2018 16:45:00 EST

2018 Quick Reference Guide: Recommended laboratory HIV testing algorithm for serum or plasma specimens
This updates the 2014 Laboratory HIV Testing algorithm guidance as a key HIV supplemental test was withdrawn from the market and replaced with a newer rapid HIV supplemental test that is automatically read, and has multiple interpretations for users.

Fri, 19 Jan 2018 10:00:00 EST

HIV Infection and HIV-Associated Behaviors Among Persons Who Inject Drugs — 20 Cities, United States, 2015
In 2015, National HIV Behavioral Surveillance found a 7% prevalence of HIV infection among persons who inject drugs which was lower than in 2012 (11%). Among HIV-negative respondents, 27% reported sharing syringes and 67% reported having vaginal sex without a condom in the previous 12 months; only 52% received syringes from a syringe services program and 34% received all syringes from sterile sources. HIV infection prevalence was higher among blacks (11%) than whites (6%) but more white persons who inject drugs shared syringes (white: 39%; black: 17%) and injection equipment (white: 61%; black: 41%) in the previous 12 months.

Fri, 12 Jan 2018 13:00:01 EST

Status of HIV Epidemic Control Among Adolescent Girls and Young Women Aged 15–24 Years — Seven African Countries, 2015–2017
Analysis of data from Population-based HIV Impact Assessment surveys conducted during 2015–2017 in seven countries in Eastern and Southern Africa found that the prevalence of HIV infection among adolescent girls and young women was 3.6%. Among those who were HIV-positive, 46.3% reported being aware of their status, and among those aware of their HIV-positive status, 85.5% reported current antiretroviral treatment (ART) use. Overall, viral load suppression among HIV-infected adolescent girls and young women, regardless of status awareness or current use of ART, was 45.0%, well below the UNAIDS target of 73%.

Fri, 12 Jan 2018 13:00:00 EST

HIV Surveillance in Adolescents and Young Adults (through 2016)
This slide set describes HIV among adolescents and young adults in the United States and 6 dependent areas.

Wed, 06 Dec 2017 15:00:00 EST
Writing About HIV/AIDS
Nelson Mandela joined hands with Bill Clinton to get free meds to HIV infected throughout Africa. Enormous achievement. I saw them both talk about it at the International AIDS Conference in Barcelona in 2002.

The International AIDS Conference mees every 2 years; the 2000 meeting was in South Africa, where odd things had been said about infection and treatment by senior South African politicians. Mr Mandela was already out of office, but gave the closing address.

In 2002 I was working as a freelance medical writer for ADIS International, which was contracted by Pfizer to write about treatment for HIV infection. The closing ceremony was in a huge stadium that had been constructed for the 1992 Olympic Games. The stadium was jammed with an enthusiastic audience.

Mr Clinton spoke first, and then Mr Mandela. They spoke of human rights and the right of every human to get access to treatment for HIV infection. Very warmly, very firmly.

And they made it happen.

In Jan 2005, 30 months later, the death of Nelson Mandela's oldest son was reported. A brilliant lawyer, he died from HIV/AIDS.